Increasing rates of Lyme disease necessitate preventive measures such as immunization to
mitigate the risk of contracting the disease. At present, there is no human Lyme disease …

ABSTRACT Introduction Transmitted by ticks, Lyme disease is the most common vector-
borne disease in the Northern hemisphere. Despite the geographical expansion of human …

A growing global health concern, Lyme disease has become the most common tick-borne
disease in the United States and Europe. Caused by the bacterial spirochete Borrelia …

There is currently no Lyme disease vaccine commercially available for use in humans. Outer
surface protein C (OspC) of the Borrelia has been widely investigated as a potential …

The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the most
common tick-borne disease in the US and Europe. No potent human vaccine is currently …

Vaccinology today has been presented with several avenues to improve protection against
infectious disease. The recent employment of the reverse vaccinology technique has …

The Lyme disease (LD) vaccine formerly approved for use in the United States consisted of
recombinant outer surface protein A (OspA) from Borrelia burgdorferi sensu stricto (ss), the …

Abstract Experimental Outer surface protein (Osp) C based subunit chimeritope vaccinogens
for Lyme disease (LD) were assessed for immunogenicity, structure, ability to elicit antibody …

The development of vaccines for prevention of diseases caused by pathogenic species can
encounter major obstacles if high sequence diversity is observed between individual strains …

Here, we describe a structure-based approach to reduce the size of an antigen protein for a
subunit vaccine. Our method consists of (i) determining the three-dimensional structure of an …